BioAge Labs
BioAge Labs is a clinical-stage biotechnology company developing oral, brain-penetrant NLRP3 and APJ agonist therapeutics for obesity and age-related metabolic diseases, supported by an AI/ML-enabled multi-omics discovery platform. Public on Nasdaq as BIOA; pre-revenue.
- Company typePublic
- Founded2015
- HeadquartersRichmond, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What BioAge Labs does
BioAge Labs, Inc. is a clinical-stage biotechnology company developing therapeutics that target the biology of human aging to treat obesity and age-related metabolic diseases. The company is headquartered in Emeryville, California, was co-founded in 2015 by Kristen Fortney, PhD, and Eric Morgen, MD, and has been listed on Nasdaq under the ticker BIOA since its October 2024 initial public offering. BioAge's pipeline is anchored by BGE-102, an oral, brain-penetrant small-molecule NLRP3 inflammasome inhibitor with a novel binding site; BGE-102 demonstrated an 86% median reduction in high-sensitivity C-reactive protein (hsCRP) in Phase 1 trials and entered a 160-adult Phase 2 proof-of-concept trial (QUELL-CV) in June 2026 for cardiovascular risk reduction, with a planned expansion into diabetic macular edema. A second program, an apelin receptor (APJ) agonist, is in preclinical development as an exercise-mimetic to enhance incretin-driven weight loss in obesity, with IND submission anticipated by year-end 2026.
BioAge's core technology is a human-first discovery platform that applies AI/ML-enabled data science to proprietary longitudinal multi-omics data captured over decades from human aging cohorts, supplemented by an in-house translational aging core in naturally aged mice for target validation. The platform has been externally validated through research collaborations with Novartis (a $550M collaboration) and Eli Lilly (Lilly Chorus combination study of azelaprag with Zepbound in obesity), and by a data partnership with Norway's HUNT Biobank. The pipeline also includes two undisclosed discovery-stage cardiometabolic programs.
BioAge is pre-revenue with no marketed products and no disclosed product pricing; future revenue is expected to come from licensing, royalty, and partnership milestone payments rather than direct sales, supported by a cash position of approximately $390M as of Q1 2026 and no long-term debt, providing a stated runway through 2029. The company is led by co-founder/CEO Kristen Fortney, PhD, alongside a leadership team that has contributed to 95+ regulatory approvals, and its board includes representation from major investors Sofinnova Investments, Longitude Capital, and VZVC.
BioAge Labs firmographics
Firmographics- Name
- BioAge Labs
- Legal name
- BioAge Labs, Inc.
- Website
- https://bioagelabs.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- BioAge Labs is a clinical-stage biotechnology company developing oral, brain-penetrant NLRP3 and APJ agonist therapeutics for obesity and age-related metabolic diseases, supported by an AI/ML-enabled multi-omics discovery platform. Public on Nasdaq as BIOA; pre-revenue.
- Ownership category
- akta.pro rank
BioAge Labs industry classification
Industry- Product category
- Metabolic Disease Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where BioAge Labs is headquartered
LocationHeadquarters
- HQ city
- Richmond
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
BioAge Labs business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- None (Pre-revenue): BioAge Labs is a clinical-stage biopharmaceutical company with no current product revenue. Revenue growth is not expected for years as the drug candidates remain in early clinical development stages. Future potential revenue streams could include licensing/royalty deals, partnership milestone payments, and ultimately product sales if drug candidates are approved.
Go-to-market motion3 records
Distribution channels1 record
Marketing channels6 records
BioAge Labs product offering
Product offeringCore offering
BioAge Labs is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics targeting the molecular biology of aging, with a current pipeline focused on an oral NLRP3 inhibitor (BGE-102) for cardiovascular risk and diabetic macular edema, an apelin receptor (APJ) agonist program as an exercise mimetic for obesity, and an oral apelin receptor agonist (azelaprag) being advanced in combination with Eli Lilly's Zepbound. The pipeline is generated and prioritized by BioAge's proprietary human-first multi-omics discovery platform, which uses AI/ML to identify molecular drivers of metabolic aging.
Product overview
BioAge Labs offers a platform-plus-pipeline architecture. The core "Discovery Platform" is a proprietary human-first, multi-omics analysis engine that uses AI/ML to identify molecular drivers of metabolic aging. This platform powers a clinical-stage pipeline of drug candidates: the lead program BGE-102 (an oral, brain-penetrant NLRP3 inhibitor in Phase 1/Phase 2 for cardiovascular risk and diabetic macular edema), the APJ agonist program (oral and parenteral apelin receptor agonists in preclinical/IND-enabling stage for obesity as exercise mimetics to enhance incretin-driven weight loss), and additional earlier discovery-stage programs (Program 1 and Program 2, undisclosed cardiometabolic targets). The platform is externally validated through ongoing research collaborations with Novartis and Eli Lilly.
Differentiator
Problem solved
Functional benefit
Brands
- On Translating Aging: A podcast sponsored by BioAge Labs featuring conversations with researchers, entrepreneurs, and investors moving longevity science from the lab to the clinic.
Products and services
- BGE-102 (oral NLRP3 inhibitor) Oral, potent, highly brain-penetrant small-molecule NLRP3 inflammasome inhibitor with a novel structure and binding site; lead indications are cardiovascular risk reduction and diabetic macular edema. As of mid-2026, BGE-102 is in a Phase 2 proof-of-concept trial (QUELL-CV) following positive Phase 1 data showing up to 86% median reductions in high-sensitivity C-reactive protein.
- APJ Agonist Program Apelin receptor (APJ) agonist program with both oral and long-acting injectable (SQ QW) formulations functioning as an exercise mimetic for obesity. In preclinical models, agonism of APJ has the potential to double weight loss and fully restore body composition when combined with an incretin.
- Azelaprag (oral apelin receptor agonist) Oral apelin receptor agonist being advanced in combination with Eli Lilly's Zepbound (tirzepatide) for obesity and metabolic diseases, conducted through Lilly's Chorus organization.
Quantifiable outcome
- 86% median reduction in high-sensitivity C-reactive protein (hsCRP) at 60mg and 120mg doses of BGE-102 in Phase 1 trial (14-21 days)
- +3 more outcomes
Companies that use BioAge Labs
Customer profileSegments4 records
Ideal customer profiles2 records
BioAge Labs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability5 records
Feature4 records
BioAge Labs partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core, flagship and minor.
- HUNT Biobank (Norway)coreBioAge partners with Norway's HUNT Biobank to study human longevity markers and feed its multi-omics discovery platform. The biobank data underpins the company's human-first approach to identifying molecular pathways that drive aging.
- NovartisflagshipNovartis has a $550M collaboration with BioAge to advance age-related therapies. BioAge's discovery platform is validated by ongoing research collaborations with Novartis, supporting development of novel therapies targeting aging biology.
- Apple Podcasts and Spotify (Podcast distribution)minorBioAge sponsors and distributes the 'On Translating Aging' podcast through Apple Podcasts and Spotify, expanding the reach of its longevity thought leadership content to global audiences.
- Eli LillyflagshipBioAge is collaborating with Eli Lilly to advance azelaprag in combination with Lilly's Zepbound (tirzepatide) for obesity and metabolic diseases. The collaboration is conducted through Lilly's Chorus organization, with BioAge's lead program azelaprag entering Phase 2 trials in combination with Zepbound. Lilly's support extends to participation in the Series D financing via Lilly Ventures.
Scale indicators12 records
Recent moves7 records
Expansion highlights6 records
BioAge Labs competitors and assessment
Company assessmentDirect peers
- Ventyx Biosciences: Clinical-stage biotech developing oral NLRP3 inhibitors (including VTX3232), directly competing with BioAge's BGE-102 in the same target, similar inflammatory disease indications, and overlapping patient populations.
- Recursion Pharmaceuticals: AI-enabled clinical-stage drug discovery company combining high-throughput biology with machine learning. Highly comparable in business model (platform-plus-pipeline), public-market status, and reliance on computational approaches to identify novel targets.
- Schrödinger, Inc. Computational drug discovery company combining physics-based modeling with machine learning to accelerate small-molecule discovery; comparable in applying computational platforms to drive pipeline asset generation in a publicly traded biotech.
- Structure Therapeutics: Clinical-stage biotech developing oral small-molecule therapies for metabolic diseases including obesity (e.g., oral GLP-1 agonist); directly comparable therapeutic area, modality and obesity / cardiometabolic strategy.
- Viking Therapeutics: Clinical-stage biotech developing therapies for metabolic and endocrine disorders, with a notable obesity candidate (VK2735); comparable stage, target indication (obesity/metabolic), and small-molecule / peptide approach.
- Madrigal Pharmaceuticals: Commercial/specialty biopharma in metabolic liver disease (resmetirom for MASH/NASH); comparable in addressing inflammation-driven metabolic disease with small-molecule therapies and operating in overlapping patient populations.
Emerging players
- Insitro: Machine-learning-driven drug discovery company focused on metabolic disease and neuroscience; overlaps with BioAge in combining proprietary human data with AI/ML to identify drug targets, particularly in metabolic indications.
- Altos Labs: Well-capitalized private biotech focused on cellular rejuvenation and aging biology; directly comparable in mission to translate aging biology into therapeutics and in leveraging proprietary human biology datasets.
- Unity Biotechnology: Clinical-stage biotech developing senolytic and anti-aging therapeutics; overlaps with BioAge in targeting molecular mechanisms of aging to treat age-related metabolic and inflammatory diseases.
Broad incumbents
- Calico Life Sciences (Alphabet): Alphabet-backed R&D organization focused on aging biology and age-related disease; comparable in scientific mission and multi-omics approach to understanding metabolic aging, though with substantially greater resources.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
BioAge Labs social profiles
Digital presenceBioAge Labs compliance and trust
Trust signalCompliance3 records
BioAge Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioAge Labs leadership team
Management profileNumber of profiles
Profiles13 records
BioAge Labs funding detail
Funding detailFunding overview
Funding rounds6 records
Investors24 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioAge Labs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioAge Labs
What does BioAge Labs do?
BioAge Labs is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics targeting the molecular biology of aging, with a current pipeline focused on an oral NLRP3 inhibitor (BGE-102) for cardiovascular risk and diabetic macular edema, an apelin receptor (APJ) agonist program as an exercise mimetic for obesity, and an oral apelin receptor agonist (azelaprag) being advanced in combination with Eli Lilly's Zepbound. The pipeline is generated and prioritized by BioAge's proprietary human-first multi-omics discovery platform, which uses AI/ML to identify molecular drivers of metabolic aging.
Is BioAge Labs a public or private company?
BioAge Labs is a public company. It is classified as public and is currently operating.
When was BioAge Labs founded?
BioAge Labs was founded in 2015. It employs 51 to 100 people.
Where is BioAge Labs based?
BioAge Labs is headquartered in Richmond, United States, in the North America region.
How does BioAge Labs make money?
One revenue line is on record: none (Pre-revenue).
Who are BioAge Labs's main competitors?
Direct peers on record are Ventyx Biosciences, Recursion Pharmaceuticals, Schrödinger, Inc., Structure Therapeutics, Viking Therapeutics and Madrigal Pharmaceuticals. Emerging players are Insitro, Altos Labs and Unity Biotechnology. Calico Life Sciences (Alphabet) is listed as a broad incumbent.
Does BioAge Labs have an API?
No public API is recorded for BioAge Labs.
What industry is BioAge Labs in?
BioAge Labs's product category is Metabolic Disease Therapeutics. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.